COMPARE Clinical Trial Results
COMPARE is the World’s First Head-to-Head Prospective, RCT (1:1) directly comparing SFA DCBs – low dose Ranger DCB vs higher dose IN.PACT DCB.1
Ranger DCB demonstrated similar primary patency as IN.PACT at 2-Years¹ with half the total drug dose².
BSC_DE_K-M_Chart_Ranger_v_IN.PACT_2_Year_V2
*Log-rank p-value compares the entire K-M curves from time zero to full 2-Year follow-up window.
1. COMPARE Clinical Trial 2-Year Results presented by Sabine Steiner, MD. LINC 2021.
2. Based on total drug dose for (4mmx60mm) or (averages for full size matrix) per the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and IN.PACT™ Admiral Instructions for Use.
COMPARE randomised controlled trial details
- 1-year primary endpoints
- Drug dose details
- Baseline characteristics
| Ranger DCB | IN.PACT | p-value | |
|---|---|---|---|
| Binary primary patency* | 83.0% (156/188) | 81.5% (141/173) | P non-inferiority ‹0.01 |
| Freedom from major adverse events | 91.0% (182/200) | 92.6% (175/189) | P non-inferiority ‹0.01 |
*Primary Endpoint Met.
- 1-year key results
- 2-year key results
- 3-year key results
- 5-year key results
| Ranger DCB (n=207) | IN.PACT (n=207) | p-value | |
|---|---|---|---|
| Mortality: all cause | 2.5% | 1.6% | 0.73 |
| Mortality: device or procedure related | 0% | 0% | N/A |
| CD-TLR | 9.0% | 7.4% | 0.59 |
Primary safety endpoint: composite of freedom from device and procedure-related death through 30 days and freedom from major target limb amputation and CD-TLR through 1-Year post index-procedure.
Primary efficacy endpoint: primary patency at 1-Year defined as absence of clinically driven target lesion revascularization (CD-TLR) or binary restenosis determined as a peak systolic velocity ratio > 2.4 evaluated by duplex ultrasound core laboratory analysis.
CD-TLR: a reintervention performed for ≥ 50% diameter stenosis (confirmed by angiography) within ± 5 mm proximal and/or distal to the target lesion after documentation of recurrent clinical symptoms of PAD (increase of 1 Rutherford class or more) and/or drop of ABI (≥20% or >0.15 when compared to maximum early post-procedural level).
